Zurn Elkay combines durable water-infrastructure demand, strong cash conversion and attractive capital returns with a favorable historical valuation, although cyclical construction demand and acquisition execution constrain near-term upside.
Ermenegildo Zegna's luxury heritage and accelerating direct-to-consumer growth support a gradual earnings recovery, but weak non-flagship brands, modest capital returns and retail fixed costs constrain upside.
Zions Bancorporation offers a resilient regional banking franchise with improving credit quality and earnings recovery potential, but commercial loan concentration and deposit-cost sensitivity constrain its valuation upside.
Zscaler pairs a founder-led zero-trust security moat, durable subscription growth and exceptional cash generation with a sharply compressed valuation, though slowing growth, heavy SBC and platform competition cap the upside.
Zoom is a highly profitable cloud communications leader with an immensely valuable hidden Anthropic stake, trading at a steep discount despite steady enterprise growth, though investors must monitor Microsoft Teams competition and online churn.
Zai Lab is flawlessly executing a transition from a regional commercialization partner to a global biopharma innovator, supported by a massive cash runway and highly promising proprietary ADCs, though near-term regulatory pricing pressures in China demand a highly cautious, catalyst-driven entry.
ZTO Express is an exceptionally profitable scale leader in Chinese logistics with a robust moat and aggressive capital returns, though macroeconomic headwinds and domestic consumption softness require ongoing vigilance.
Zeta's profitable, fast-growing AI infrastructure trades at a peer discount, but regulatory risks around proprietary data collection and consent remain headwinds.
Zillow commands an unassailable top-of-funnel real estate monopoly trading at a deeply discounted valuation, but investors must remain sidelined until management proves they can navigate the existential FTC antitrust litigation.
Zoetis is a highly profitable leader in animal health currently trading at historic valuation lows, but investors must navigate severe headwinds from intensifying dermatology competition and escalating regulatory scrutiny over its osteoarthritis therapeutics.
Zimmer Biomet is a deeply undervalued, cash-printing orthopedic titan executing a crucial commercial turnaround, though aggressive investors must remain highly vigilant regarding severe integration risks and margin-crushing trade tariffs.
Zebra Technologies commands a near-monopoly in frontline enterprise digitization and is accelerating highly profitable recurring software growth, presenting a vastly undervalued compounder despite manageable, transient macroeconomic and tariff headwinds.